ICML 2023 | The current state of MRD in Hodgkin lymphoma
Sven Borchmann, MD, University of Cologne, Cologne, Germany, explains why measurable residual disease (MRD) in Hodgkin lymphoma has not reached the same status as in other malignancies, such as B-cell lymphomas. Dr Borchmann expresses hope that we will see more developments in this field in the next few years. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
Obviously, when a new technology comes around, I think, first of all, there is a lot of methodological establishment and I think this is first focused on diseases that are first of all common, and second of all, where circulating tumor DNA, which is used to assess MRD is easily available. So a lot of focus has been on aggressive B-cell lymphomas, large B-cell lymphoma. And I think other diseases like Hodgkin lymphoma are a little bit behind...
Obviously, when a new technology comes around, I think, first of all, there is a lot of methodological establishment and I think this is first focused on diseases that are first of all common, and second of all, where circulating tumor DNA, which is used to assess MRD is easily available. So a lot of focus has been on aggressive B-cell lymphomas, large B-cell lymphoma. And I think other diseases like Hodgkin lymphoma are a little bit behind. So just because of obviously, with a new technique, you first go where it’s easy. And I think Hodgkin lymphoma is a little bit more hard. So I think now we see more and more studies and we have done something in that field, other labs have done the same and I think we’re now going to see more in that area over the next couple of years. And there’s also some data, obviously, at this meeting that has been presented.
Read more...
